Cancer research
HUS Comprehensive Cancer Center is Finland’s largest cancer research center, with more than 150 ongoing studies annually. We carry out cancer treatment and clinical cancer pharmaceutical studies as academic research and in cooperation with pharmaceutical companies. A new cancer drug that does not yet have marketing authorization is the subject in many research projects. With clinical pharmaceutical studies, we are increasing patients’ access to treatments with medicines that are not yet publicly available.

Our cancer trials that are recruiting patients
You can apply to become a research patient in clinical cancer research by referral from a physician. The attending physician will also provide us with the necessary information on the eligibility to participate in a study. Below you will find a list of our open-line cancer studies that are recruiting patients. For more information, please contact unyhnaghgxvzhfcbgvynnxfv@uhf.svif.suh@iskaalitopsumiktutnaulah .
CYPIDES
This is a phase 1 safety and pharmacokinetics study with ODM-208 trial medication in patients with metastatic castration-resistant prostate cancer.
Principal investigator: Tapio Utriainen
No ongoing studies at this time.
MK-3475-C93
A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab Versus Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma in the First-line Setting
Principal Investigator: Heini Lassus
NIS793B12301
Principal investigator: Katriina Peltola
ALL (ACUTE LYMPHOBLASTIC LEUKEMIA)
ALLTOGETHER
A treatment study protocol of children (1–17 years of age) and young adults (18–45 years of age) with acute lymphoblastic leukemia (ALL)
Person responsible for the study: Ulla Wartiovaara-Kautto
https://clinicaltrials.gov/ct2/show/NCT04307576
EWALL-PH-03
An open label, three-arm, randomized phase II study to compare the safety and efficacy of ponatinib in combination with either chemotherapy or blinatumomab with imatinib plus chemotherapy as primary therapy for patients aged 55 years and older who have Philadelphia chromosome-positive (Ph+ or BCR- ABL1+) acute lymphoblastic leukemia (ALL)
Person responsible for the study: Kimmo Porkka
https://www.clinicaltrialsregister.eu/ctr-search/search?query=2018-0033…
SCANALL
SCAN ALL – Nordic study on the occurrence of mutations in patients with Philadelphia chromosome-positive acute lymphocytic leukemia (Ph+ALL) and chronic myeloid leukemia (CML)
Person responsible for the study: Kimmo Porkka
AML (ACUTE MYELOID LEUKEMIA)
BEXMAB
A phase l/ll open-label study to assess safety, tolerability and preliminary efficacy of the clever-1 antibody bexmarilimab in combination with azacitidine or azacitidine/venetoclax in patients with myelodysplastic syndrome or chronic myelomonocytic leukemia or acute myeloid leukemia.
Principal Investigator: Mika Kontro
https://www.clinicaltrialsregister.eu/ctr-search/trial/2021-002104-12/FI
CVOB560A12101
A phase 1b multicenter study of VOB560 study preparation in combination with MIK665 study preparation in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL), acute myeloid leukemia (AML), or multiple myeloma (MM)
Person responsible for the study: Kimmo Porkka
https://www.clinicaltrials.gov/ct2/show/NCT04702425
HO150, AMLSG 29-18
An open-label, randomized, double-blind placebo-controlled multicenter study of ivosidenib or enasidenib in combination with induction and consolidation chemotherapy followed by a maintenance therapy in patients with newly diagnosed IDH1- or IDH2-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS-EB2) with excess blasts, and who are eligible for intensive chemotherapy.
Person responsible for the study: Mika Kontro
https://clinicaltrials.gov/ct2/show/NCT03839771
HO156, AMLSG 28-18
A phase III open-label, randomized multicenter study with gilteritinib or midostaurine in combination with induction and consolidation chemotherapy followed by a one-year maintenance treatment period in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) or myelodysplastic syndrome with excess blasts (MDS-EB2), and who are eligible for intensive chemotherapy.
Person responsible for the study: Mika Kontro
https://clinicaltrials.gov/ct2/show/NCT03839771
LOXO-IDH-20001
A phase 1 study for assessment of oral LY3410738 in patients with advanced hematologic malignancies with IDH1 or IDH2 mutations
Person responsible for the study: Kimmo Porkka
https://clinicaltrials.gov/ct2/show/NCT04603001
MYELOFIBROSIS
INCB 57643-103
Open-label phase I study on the safety and tolerability of INCB57643 in subjects with myelofibrosis
Person responsible for the study: Minna Lehto
https://clinicaltrials.gov/ct2/show/NCT04279847
INCB 50465-304
Randomized, double-blind, placebo-controlled study on the use of the combination of PI3Kδ inhibitor parsaclisib and ruxolitinib in participants with myelofibrosis who have suboptimal response to ruxolitinib
Person responsible for the study: Minna Lehto
https://clinicaltrials.gov/ct2/show/NCT04551053
INCB 50465-313
Phase 3 randomized, double-blind, placebo-controlled study on the use of the combination of PI3Kδ inhibitor parsaclisib and ruxolitinib in participants with myelofibrosis
Person responsible for the study: Minna Lehto
https://clinicaltrials.gov/ct2/show/NCT04551066
MYELOMA
CC-92480-MM-001
Open-label study to assess the safety, pharmacokinetics and preliminary efficacy of CC-92480 in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma
Person responsible for the study: Pekka Anttila
https://clinicaltrials.gov/ct2/show/NCT03374085
COBRA
Phase 3 randomized open-label study comparing combination Crd and Vrd medications (carfilzomicb + lenalidomide + dexamethasone vs. bortezomib + lenalidomide + dexamethasone) in the treatment of newly diagnosed multiple myeloma
Person responsible for the study: Juha Lievonen
https://clinicaltrials.gov/ct2/show/NCT03729804
CARTITUDE-5
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants with Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.
Principal Investigator: Mikko Keränen
https://clinicaltrials.gov/ct2/show/NCT04923893
MagnetisMM-5
An open-label, 3-arm, multicenter, randomized Phase 3 study to evaluate the efficacy and safety of elranatamab (PF-06863135) monotherapy and elranatamab + daratumumab versus daratumumab + pomalidomide + dexamethasone in participants with relapsed/refractory multiple myeloma who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor.
Principal Investigator: Juha Lievonen
https://clinicaltrials.gov/ct2/show/NCT05020236
MagnetisMM-7
A randomized, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimimal residual disease positive after undergoing autologous stem-cell transplantation.
Principal Investigator: Juha Lievonen
https://clinicaltrials.gov/ct2/show/NCT05317416
CLL (CHRONIC LYMPHOCYTIC LEUKEMIA)
CJBH492A12101
Description of the study: Open-label study on treatment with JBH492 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL)
Person responsible for the study: Vesa Lindström
ASTEROID
Open-label randomized phase II study in which durvalumab is administered after stereotactic body radiotherapy as adjuvant therapy to non-small cell, grade I lung cancer
Principal investigator: Anu Anttonen
-
NP30179
Phase I open-label multicenter study assessing the safety, tolerability and pharmacokinetics of RO7082859 when administered as a single agent and in combination with obinutuzumab at escalating doses to subjects with relapsed or refractory B-cell non-Hodgkin’s lymphoma who have received a fixed single dose pre-treatment of obinutuzumab
Principal investigator: Sirpa Leppä
https://clinicaltrials.gov/ct2/show/NCT03075696
POLAR BEAR
An open-label randomized phase III study comparing R-MINI-CHOP to R-MINI-CHP therapy in combination with polazuzumab-vedotin as primary treatment for elderly patients with diffuse large cell B-cell lymphoma.
Principal investigator: Sirpa Leppä
https://clinicaltrials.gov/ct2/show/NCT04332822
CJBH492A12101
Multicenter phase I/Ib open-label study with JBH492 at escalating doses in patients with recurrent or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL)
Principal investigator: Sirpa Leppä
https://clinicaltrials.gov/ct2/show/NCT04240704
GCT3013-01
Phase 1/2 open-label dose-escalation study with GEN3013 in patients with relapsed, progressive or refractory B-cell lymphoma
Principal investigator: Sirpa Leppä
https://clinicaltrials.gov/ct2/show/NCT03625037
GCT3013-02
Phase 1b/2 open-label study to assess the safety and preliminary efficacy of epcoritamab (GEN3013; DuoBody-CD3xCD20®) in combination with other agents in subjects with B-cell non-Hodgkin’s lymphoma
Principal investigator: Sirpa Leppä
https://clinicaltrials.gov/ct2/show/NCT04663347
GCT3013-05
Randomized, open-label phase 3 study to assess the efficacy of epkoritamab compared to investigator’s choice chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma
Principal investigator: Sirpa Leppä
https://clinicaltrials.gov/ct2/show/NCT04628494
XHUTCHISON 2018-689-00US1
Open-label phase 1 study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HMPL-689 in patients with relapsed or refractory lymphoma
Principal investigator: Sirpa Leppä
https://clinicaltrials.gov/ct2/show/NCT03786926
ALTAMIRA
Acalabrutinib and rituximab in elderly patients with untreated mantle cell lymphoma
Principal Investigator: Annika Pasanen
https://clinicaltrials.gov/ct2/show/NCT05214183
INCMOR 0208-301
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma
Principal Investigator: Annika Pasanen
STARBOARD
A Phase 3, Randomized, Double-blind Study of Encorafenib and Binimetinib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With BRAF V600E/K Mutation-Positive Metastatic OR Unresectable Locally Advanced Melanoma
Principal Investigator: Micaela Hernberg
MK6482-005
An open-label, randomized phase 3 study of MK-6482 versus everolimus in participants with advanced renal cell carcinoma that has progressed after prior treatment.
Principal investigator: Katriina Peltola
https://clinicaltrials.gov/ct2/show/NCT04195750
MK6482-011
Drug study comparing the MK-6482 study preparation and the combination of lenvatinib and kabotzantinib in advanced renal cell carcinoma
Principal investigator: Katriina Peltola
https://clinicaltrials.gov/ct2/show/NCT04586231
MK6482-012
An open-label randomized phase 3 study on the efficacy and safety of a combination therapy of pembrolizumab, lenvatinib and beltsutifan (MK-6482) compared to a combination therapy of MK-1308A and lenvatinib or a combination therapy of pembrolizumab and lenvatinib in advanced renal cell carcinoma
Principal investigator: Katriina Peltola
https://clinicaltrials.gov/ct2/show/NCT04736706
MK6482-022
A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare Efficacy and Safety of Belzutifan (MK-6482) plus Pembrolizumab Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma (ccRCC) Post-Nephrectomy
Principal Investigator: Katriina Peltola
https://www.clinicaltrials.gov/ct2/show/NCT05239728
KRYSTAL-10
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy
Principal Investigator: Siru Mäkelä
https://clinicaltrials.gov/ct2/show/NCT04793958
BREAKWATER
Open-label, multicenter, randomized phase 3 study of first-line Encorafenib plus Cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of Encorafenib and Cetuximab plus chemotherapy in participants with metastatic BRAF V600E-mutant colorectal cancer
Principal Investigator: Siru Mäkelä
https://clinicaltrials.gov/ct2/show/NCT04607421
Neo-ACT
Physical Exercise During Neoadjuvant Chemotherapy for Breast Cancer as a Means to Increase Pathological Complete Response Rates: the Randomized Neo-ACT Trial
Principal investigator: Peeter Karihtala
https://clinicaltrials.gov/ct2/show/NCT05184582
Advanced breast cancer
EPIK-B5
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With HR-positive, HER2-negative Advanced Breast Cancer With a PIK3CA Mutation, Who Progressed on or After Aromatase Inhibitor and a CDK4/6 Inhibitor
Principal Investigator: Meri Utriainen
https://clinicaltrials.gov/ct2/show/NCT05038735
Early breast cancer
Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Women with Breast Cancer Taking an Aromatase Inhibitor
Principal Investigator: Maria Faltinova
https://www.clinicaltrialsregister.eu/ctr-search/search?query=2019-0012…
BRIGHTLINE-1
Brightline-1: A Phase II/III, Randomized, Open-label, Multi-center Study of BI 907828 Compared to Doxorubicin as First Line Treatment of Patients With Advanced Dedifferentiated Liposarcoma
Principal Investigator: Kirsi Santti
https://clinicaltrials.gov/ct2/show/NCT05218499
FINPROVE
A national phase 2 drug study on individual cancer treatment in advanced cancer.
Principal investigator: Katriina Peltola
https://clinicaltrials.gov/ct2/show/NCT05159245
MATINS
Phase I/II open-label, three-phase study to determine tolerated dose and follow-up separate cohorts to assess the safety, tolerability and preliminary efficacy of CLEVER-1 antibody FP-1305 in subjects with advanced cancer (gastrointestinal cancer, melanoma or ovarian cancer)
Principal investigator: Annika Pasanen
https://clinicaltrials.gov/ct2/show/NCT03733990
TILT
Phase I dose-escalation study to determine the safety of tumor necrosis factor alpha and interleukin-2 cytokine-coding oncolytic adenovirus (TILT-123) in patients with injectable solid tumor refractory to other therapies
Principal investigator: Katriina Peltola
-
Becoming our partner
We cooperate with the pharmaceutical industry and product development. You can contact us and suggest a research topic.
The Comprehensive Cancer Center has currently approximately 150 ongoing studies, of which drug trials are a significant portion. In all our research activities, we adhere to the best ethical principles. We carry out the studies in accordance with good clinical practice, considering the interests of the research patient a priority. In our research activities, we also follow the Declaration of Helsinki.
New studies can be offered to the Comprehensive Cancer Center by sending a message to uudetsyopatutkimukset@hus.fi, or directly to the researcher.
Obtaining a hospital research permit for a pharmaceutical trial requires the approval of the Ethics Committee and FIMEA, as well as a financial agreement. The total duration of the permit processing from the research offer to its approval is approximately two months. Permits and agreements can be prepared and processed simultaneously.
In cooperation
Southern Finland Regional Cancer Center FICAN South (opens in new window, links to another website)
The Southern Finland Regional Cancer Center FICAN South promotes cancer research in Southern Finland, and coordinates the diagnosis and treatment of cancer.

iCAN Digital Precision Cancer Medicine (opens in new window, links to another website)
The iCAN research project aims to improve the treatment of cancer patients and support the development of new innovations stemming from high-quality cancer research.

Helsinki Biobank (opens in new window, links to another website)
In our research, we utilize samples and data resources stored in the biobank. Read more about biobank operations on the website of Helsinki Biobank.

Read more about our research
New medication for the treatment of advanced melanoma

Clinical Trial Unit
The Clinical Trial Unit operates as an integral part of the Comprehensive Cancer Center. Our unit conducts phase I-IV clinical cancer treatment studies and treats all cancer diagnoses.
